By labeling CTCs with other specific surface antibodies, such as the human epidermal growth factor receptor 2 (HER-2) in the case of breast cancer (see section “Isolation of CTCs from patients”), or even with an antibody cocktail, the probability to capture EpCAM negative cells will increase. This evidence concerns the gene ERBB2 and breast carcinoma.